131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: A mono-institutional experience with 43 patients

A. Garaventa, O. Bellagamba, M. S. Lo Piccolo, C. Milanaccio, E. Lanino, L. Bertolazzi, G. P. Villavecchia, M. Cabria, G. Scopinaro, F. Claudiani, B. De Bernardi

Research output: Contribution to journalArticle

Abstract

Incomplete response to therapy may compromise the outcome of children with advanced neuroblastoma. In an attempt to improve tumour response we incorporated 131I-metaiodobenzylguanidine (131I-MIBG) in the treatment regimens of selected stage 3 and stage 4 patients. Between 1986 and 1997, 43 neuroblastoma patients older than 1 year at diagnosis, 13 with stage 3 (group A) and 30 with stage 4 disease (group B) who had completed the first-line protocol without achieving complete response entered in this study. 131I-MIBG dose/course ranged from 2.5 to 5.5 Gbq (median, 3.7). The number of courses ranged from 1 to 5 (median 3) depending on the tumour response and toxicity. The most common acute side-effect was thrombocytopenia. Later side-effects included severe interstitial pneumonia in one patient, acute myeloid leukaemia in two, reduced thyroid reserve in 21. Complete response was documented in one stage 4 patient, partial response in 12 (two stage 3, 10 stage 4), mixed or no response in 25 (ten stage 3, 15 stage 4) and disease progression in five (one stage 3, four stage 4). Twenty-four patients (12/13 stage 3, 12/30 stage 4) are alive at 22-153 months (median, 59) from diagnosis. 131I-MIBG therapy may increase the cure rate of stage 3 and improve the response of stage 4 neuroblastoma patients with residual disease after first-line therapy. A larger number of patients should be treated to confirm these results but logistic problems hamper prospective and coordinated studies. Long-term toxicity can be severe.

Original languageEnglish
Pages (from-to)1378-1384
Number of pages7
JournalBritish Journal of Cancer
Volume81
Issue number8
Publication statusPublished - 1999

Fingerprint

Neuroblastoma
Therapeutics
Interstitial Lung Diseases
Acute Myeloid Leukemia
Thrombocytopenia
Disease Progression
Neoplasms
Thyroid Gland
Prospective Studies

Keywords

  • I-metaiodobenzylguanidine
  • Neuroblastoma
  • Radiometabolic therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma : A mono-institutional experience with 43 patients. / Garaventa, A.; Bellagamba, O.; Lo Piccolo, M. S.; Milanaccio, C.; Lanino, E.; Bertolazzi, L.; Villavecchia, G. P.; Cabria, M.; Scopinaro, G.; Claudiani, F.; De Bernardi, B.

In: British Journal of Cancer, Vol. 81, No. 8, 1999, p. 1378-1384.

Research output: Contribution to journalArticle

Garaventa, A, Bellagamba, O, Lo Piccolo, MS, Milanaccio, C, Lanino, E, Bertolazzi, L, Villavecchia, GP, Cabria, M, Scopinaro, G, Claudiani, F & De Bernardi, B 1999, '131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: A mono-institutional experience with 43 patients', British Journal of Cancer, vol. 81, no. 8, pp. 1378-1384.
Garaventa, A. ; Bellagamba, O. ; Lo Piccolo, M. S. ; Milanaccio, C. ; Lanino, E. ; Bertolazzi, L. ; Villavecchia, G. P. ; Cabria, M. ; Scopinaro, G. ; Claudiani, F. ; De Bernardi, B. / 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma : A mono-institutional experience with 43 patients. In: British Journal of Cancer. 1999 ; Vol. 81, No. 8. pp. 1378-1384.
@article{d1abc571398242a59293e4627dd5ab8e,
title = "131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma: A mono-institutional experience with 43 patients",
abstract = "Incomplete response to therapy may compromise the outcome of children with advanced neuroblastoma. In an attempt to improve tumour response we incorporated 131I-metaiodobenzylguanidine (131I-MIBG) in the treatment regimens of selected stage 3 and stage 4 patients. Between 1986 and 1997, 43 neuroblastoma patients older than 1 year at diagnosis, 13 with stage 3 (group A) and 30 with stage 4 disease (group B) who had completed the first-line protocol without achieving complete response entered in this study. 131I-MIBG dose/course ranged from 2.5 to 5.5 Gbq (median, 3.7). The number of courses ranged from 1 to 5 (median 3) depending on the tumour response and toxicity. The most common acute side-effect was thrombocytopenia. Later side-effects included severe interstitial pneumonia in one patient, acute myeloid leukaemia in two, reduced thyroid reserve in 21. Complete response was documented in one stage 4 patient, partial response in 12 (two stage 3, 10 stage 4), mixed or no response in 25 (ten stage 3, 15 stage 4) and disease progression in five (one stage 3, four stage 4). Twenty-four patients (12/13 stage 3, 12/30 stage 4) are alive at 22-153 months (median, 59) from diagnosis. 131I-MIBG therapy may increase the cure rate of stage 3 and improve the response of stage 4 neuroblastoma patients with residual disease after first-line therapy. A larger number of patients should be treated to confirm these results but logistic problems hamper prospective and coordinated studies. Long-term toxicity can be severe.",
keywords = "I-metaiodobenzylguanidine, Neuroblastoma, Radiometabolic therapy",
author = "A. Garaventa and O. Bellagamba and {Lo Piccolo}, {M. S.} and C. Milanaccio and E. Lanino and L. Bertolazzi and Villavecchia, {G. P.} and M. Cabria and G. Scopinaro and F. Claudiani and {De Bernardi}, B.",
year = "1999",
language = "English",
volume = "81",
pages = "1378--1384",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - 131I-metaiodobenzylguanidine (131I-MIBG) therapy for residual neuroblastoma

T2 - A mono-institutional experience with 43 patients

AU - Garaventa, A.

AU - Bellagamba, O.

AU - Lo Piccolo, M. S.

AU - Milanaccio, C.

AU - Lanino, E.

AU - Bertolazzi, L.

AU - Villavecchia, G. P.

AU - Cabria, M.

AU - Scopinaro, G.

AU - Claudiani, F.

AU - De Bernardi, B.

PY - 1999

Y1 - 1999

N2 - Incomplete response to therapy may compromise the outcome of children with advanced neuroblastoma. In an attempt to improve tumour response we incorporated 131I-metaiodobenzylguanidine (131I-MIBG) in the treatment regimens of selected stage 3 and stage 4 patients. Between 1986 and 1997, 43 neuroblastoma patients older than 1 year at diagnosis, 13 with stage 3 (group A) and 30 with stage 4 disease (group B) who had completed the first-line protocol without achieving complete response entered in this study. 131I-MIBG dose/course ranged from 2.5 to 5.5 Gbq (median, 3.7). The number of courses ranged from 1 to 5 (median 3) depending on the tumour response and toxicity. The most common acute side-effect was thrombocytopenia. Later side-effects included severe interstitial pneumonia in one patient, acute myeloid leukaemia in two, reduced thyroid reserve in 21. Complete response was documented in one stage 4 patient, partial response in 12 (two stage 3, 10 stage 4), mixed or no response in 25 (ten stage 3, 15 stage 4) and disease progression in five (one stage 3, four stage 4). Twenty-four patients (12/13 stage 3, 12/30 stage 4) are alive at 22-153 months (median, 59) from diagnosis. 131I-MIBG therapy may increase the cure rate of stage 3 and improve the response of stage 4 neuroblastoma patients with residual disease after first-line therapy. A larger number of patients should be treated to confirm these results but logistic problems hamper prospective and coordinated studies. Long-term toxicity can be severe.

AB - Incomplete response to therapy may compromise the outcome of children with advanced neuroblastoma. In an attempt to improve tumour response we incorporated 131I-metaiodobenzylguanidine (131I-MIBG) in the treatment regimens of selected stage 3 and stage 4 patients. Between 1986 and 1997, 43 neuroblastoma patients older than 1 year at diagnosis, 13 with stage 3 (group A) and 30 with stage 4 disease (group B) who had completed the first-line protocol without achieving complete response entered in this study. 131I-MIBG dose/course ranged from 2.5 to 5.5 Gbq (median, 3.7). The number of courses ranged from 1 to 5 (median 3) depending on the tumour response and toxicity. The most common acute side-effect was thrombocytopenia. Later side-effects included severe interstitial pneumonia in one patient, acute myeloid leukaemia in two, reduced thyroid reserve in 21. Complete response was documented in one stage 4 patient, partial response in 12 (two stage 3, 10 stage 4), mixed or no response in 25 (ten stage 3, 15 stage 4) and disease progression in five (one stage 3, four stage 4). Twenty-four patients (12/13 stage 3, 12/30 stage 4) are alive at 22-153 months (median, 59) from diagnosis. 131I-MIBG therapy may increase the cure rate of stage 3 and improve the response of stage 4 neuroblastoma patients with residual disease after first-line therapy. A larger number of patients should be treated to confirm these results but logistic problems hamper prospective and coordinated studies. Long-term toxicity can be severe.

KW - I-metaiodobenzylguanidine

KW - Neuroblastoma

KW - Radiometabolic therapy

UR - http://www.scopus.com/inward/record.url?scp=0032585696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032585696&partnerID=8YFLogxK

M3 - Article

C2 - 10604736

AN - SCOPUS:0032585696

VL - 81

SP - 1378

EP - 1384

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 8

ER -